32G Multi Rate Very Short Reach SerDes PHY - GlobalFoundries 12LP and 12LPP
Lip-Bu Tan quit Intel board after "differences" with CEO, says Reuters
By Peter Clarke, eeNews Europe (August 28, 2024)
Respected semiconductor executive and investor Lip-Bu Tan has resigned from the board of struggling chip company Intel after differences with CEO Pat Gelsinger over the company’s revival plan, according to Reuters.
Intel posted a Securities and Exchange Commission filing on August 22 saying that Tan had informed the company on August 19 that he had resigned from the board effective immediately. In the filing Intel quoted Tan saying: “This is a personal decision based on a need to reprioritize various commitments and I remain supportive of the company and its important work.”
![]() |
E-mail This Article | ![]() |
![]() |
Printer-Friendly Page |
Related News
- Intel's New CEO Called "Strong Choice" to Respin Company
- Intel Elects Lip-Bu Tan to Its Board of Directors
- Celestial AI Announces Appointment of Semiconductor Industry Icon Lip-Bu Tan to Board of Directors
- Cadence Announces Anirudh Devgan to Become CEO in December 2021; Lip-Bu Tan to Transition to Role of Executive Chairman at That Time
- Lip-Bu Tan Joins Aquantia Board of Directors
Breaking News
- RISC-V International Promotes Andrea Gallo to CEO
- See the 2025 Best Edge AI Processor IP at the Embedded Vision Summit
- Andes Technology Showcases RISC-V AI Leadership at RISC-V Summit Europe 2025
- RISC-V Royalty-Driven Revenue to Exceed License Revenue by 2027
- Keysom Unveils Keysom Core Explorer V1.0
Most Popular
- RISC-V Royalty-Driven Revenue to Exceed License Revenue by 2027
- SiFive and Kinara Partner to Offer Bare Metal Access to RISC-V Vector Processors
- Imagination Announces E-Series: A New Era of On-Device AI and Graphics
- Siemens to accelerate customer time to market with advanced silicon IP through new Alphawave Semi partnership
- Cadence Unveils Millennium M2000 Supercomputer with NVIDIA Blackwell Systems to Transform AI-Driven Silicon, Systems and Drug Design